HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), announces an upcoming investor workshop for Qualified Institutional Investors at Mar-A-Lago Club during the week of January 6, 2025. The event aims to support planned acquisitions for a national network of interventional psychiatry practices focused on treating suicidal depression and PTSD.
The company has secured non-binding Letters of Intent and banking intent for initial clinic acquisitions, targeting facilities that generate over $100 million revenue run-rate in 2025. Future acquisitions will focus on clinics with established patient populations offering multimodal care, including ketamine treatment and Transcranial Magnetic Stimulation (TMS).
The workshop requires a minimum commitment of $5 million in secured acquisition funding from qualified investors. The presentation will comply with JOBS act 'testing the waters' provisions, and federal security clearance will be required for attendance.
HOPE Therapeutics, una sussidiaria di NRx Pharmaceuticals (NASDAQ:NRXP), annuncia un imminente workshop per investitori riservato a Investitori Istituzionali Qualificati presso il Mar-A-Lago Club durante la settimana del 6 gennaio 2025. L'evento ha lo scopo di supportare acquisizioni pianificate per una rete nazionale di pratiche di psichiatria interventistica focalizzate sul trattamento della depressione suicidaria e del PTSD.
L'azienda ha ottenuto lettere di intenti non vincolanti e intenti bancari per le acquisizioni iniziali di cliniche, puntando a strutture che generano oltre $100 milioni di entrate previste nel 2025. Le future acquisizioni si concentreranno su cliniche con popolazioni di pazienti consolidate che offrono assistenza multimodale, compresi i trattamenti con ketamina e la Stimolazione Magnetica Transcranica (TMS).
Il workshop richiede un impegno minimo di $5 milioni in finanziamenti per acquisizioni garantiti da investitori qualificati. La presentazione sar脿 conforme alle disposizioni 'testing the waters' della legge JOBS, e sar脿 necessaria un'autorizzazione di sicurezza federale per la partecipazione.
HOPE Therapeutics, una subsidiaria de NRx Pharmaceuticals (NASDAQ:NRXP), anuncia un pr贸ximo taller para inversores dirigido a Inversores Institucionales Calificados en el Mar-A-Lago Club durante la semana del 6 de enero de 2025. El evento tiene como objetivo apoyar las adquisiciones planificadas para una red nacional de pr谩cticas de psiquiatr铆a intervencionista centradas en el tratamiento de la depresi贸n suicidal y el PTSD.
La empresa ha asegurado Cartas de Intenci贸n no vinculantes y la intenci贸n bancaria para las adquisiciones iniciales de cl铆nicas, apuntando a instalaciones que generen m谩s de $100 millones de ingresos proyectados en 2025. Las futuras adquisiciones se centrar谩n en cl铆nicas con poblaciones de pacientes establecidas que ofrezcan atenci贸n multimodal, incluidos tratamientos con ketamina y estimulaci贸n magn茅tica transcraneal (TMS).
El taller requiere un compromiso m铆nimo de $5 millones en financiamiento asegurado para adquisiciones de inversores calificados. La presentaci贸n cumplir谩 con las disposiciones de la ley JOBS 'testing the waters', y se requerir谩 autorizaci贸n de seguridad federal para la asistencia.
HOPE Therapeutics电� NRx Pharmaceuticals (NASDAQ:NRXP)鞚� 鞛愴殞靷靹� 2025雲� 1鞗� 6鞚� 欤缄皠鞐� Mar-A-Lago Club鞐愳劀 鞛愱博 鞛埖鐢 旮瓣磤 韴瀽鞛愲ゼ 鞙勴暅 韴瀽鞛� 鞗岉伂靾嶌潉 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 頄夓偓电� 鞛愳偞 鞖办毟歃� 氚� 鞕胳儊 頉� 鞀ろ姼霠堨姢 鞛レ暊(PTSD) 旃橂鞐� 齑堨爯鞚� 毵烄稑 甑皜鞝� 鞝曥嫚鞚橅暀 旃橂 雱ろ姼鞗岉伂鞚� 瓿勴殟霅� 鞚胳垬毳� 歆�鞗愴晿电� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
須岇偓电� 齑堦赴 韥措Μ雼� 鞚胳垬毳� 鞙勴暅 牍勱惮靻嶌爜 鞚橅枼靹� 氚� 鞚�頄� 鞚橅枼靹滊ゼ 頇曤炒頄堨溂氅�, 2025雲勳棎 $100 氚彪 鞚挫儊鞚� 靾橃澋鞚� 靸濎劚頃樀鐢 鞁滌劋鞚� 韮�瓴熿溂搿� 頃橁碃 鞛堨姷雼堧嫟. 頄ロ泟 鞚胳垬电� 旒�韮�氙� 旃橂 氚� 瓴诫憪臧� 鞛愱赴 鞛愱饭(TMS)鞚� 韽暔頃� 雼れ 鞏戩嫕 甏�毽� 靹滊箘鞀るゼ 鞝滉车頃樀鐢 頇曤霅� 頇橃瀽 歆戨嫧鞚� 鞛埖鐢 韥措Μ雼夓棎 欷戩爯鞚� 霊� 瓴冹瀰雼堧嫟.
鞗岉伂靾嶌潃 鞛愱博 鞛埖鐢 韴瀽鞛愲攵�韯� 頇曤炒霅� 鞚胳垬 鞛愱笀鞚� 斓滌唽 鞎届爼 $5 氚彪鞚� 鞖旉惮頃╇媹雼�. 頂勲爤鞝犿厡鞚挫厴鞚� JOBS 氩曥潣 'testing the waters' 臁绊暛鞚� 欷�靾橅晿氅�, 彀胳劃鞚� 鞙勴暣靹湹鐢 鞐半癌 氤挫晥 鞀轨澑鞚� 頃勳殧頃╇媹雼�.
HOPE Therapeutics, une filiale de NRx Pharmaceuticals (NASDAQ:NRXP), annonce un prochain atelier pour investisseurs destin茅 aux Investisseurs Institutionnels Qualifi茅s au Mar-A-Lago Club durant la semaine du 6 janvier 2025. L'茅v茅nement vise 脿 soutenir les acquisitions pr茅vues pour un r茅seau national de pratiques de psychiatrie interventionnelle ax茅es sur le traitement de la d茅pression suicidaire et du PTSD.
L'entreprise a s茅curis茅 des lettres d'intention non contraignantes et des intentions bancaires pour les acquisitions initiales de cliniques, ciblant des 茅tablissements g茅n茅rant plus de $100 millions de revenus annuels en 2025. Les futures acquisitions se concentreront sur des cliniques ayant des populations de patients 茅tablies offrant des soins multimodaux, y compris le traitement par k茅tamine et la stimulation magn茅tique transcr芒nienne (TMS).
L'atelier n茅cessite un engagement minimum de $5 millions en financement d'acquisition s茅curis茅 de la part des investisseurs qualifi茅s. La pr茅sentation sera conforme aux dispositions de la loi JOBS 'testing the waters', et une autorisation de s茅curit茅 f茅d茅rale sera requise pour assister.
HOPE Therapeutics, eine Tochtergesellschaft von NRx Pharmaceuticals (NASDAQ:NRXP), k眉ndigt einen bevorstehenden Investoren-Workshop f眉r qualifizierte institutionelle Investoren im Mar-A-Lago Club in der Woche vom 6. Januar 2025 an. Die Veranstaltung hat zum Ziel, geplante Akquisitionen f眉r ein nationales Netzwerk von interventionistischen psychiatrischen Praxen zu unterst眉tzen, die sich auf die Behandlung von suizidaler Depression und PTSD konzentrieren.
Das Unternehmen hat nicht-bindende Absichtserkl盲rungen und bankseitige Absichten f眉r erste Klinikakquisitionen gesichert, wobei Einrichtungen angestrebt werden, die 眉ber $100 Millionen Umsatzlaufzeit im Jahr 2025 generieren. Zuk眉nftige Akquisitionen werden sich auf Kliniken mit etablierten Patientenpopulationen konzentrieren, die multimodale Betreuung anbieten, darunter Ketaminbehandlung und Transkranielle Magnetstimulation (TMS).
Der Workshop erfordert ein Mindestengagement von $5 Millionen an gesichertem Akquisitionsfinanzierung von qualifizierten Investoren. Die Pr盲sentation entspricht den Bestimmungen des JOBS-Gesetzes 'testing the waters', und eine bundesstaatliche Sicherheitsfreigabe wird f眉r die Teilnahme ben枚tigt.
- Company has secured non-binding Letters of Intent for clinic acquisitions
- Target acquisitions expected to generate over $100 million revenue run-rate in 2025
- Strategic expansion into established clinics with existing patient bases and multiple treatment modalities
- Letters of Intent are non-binding, indicating uncertainty in deal completion
- Significant capital requirements ($5M minimum) needed for acquisition strategy
Insights
The planned acquisition strategy by HOPE Therapeutics represents a significant business expansion into the mental health treatment sector. The target of acquiring clinics with
The focus on ketamine treatment and TMS clinics aligns with the growing mental health treatment market, particularly for treatment-resistant depression and PTSD. The acquisition strategy could provide rapid revenue scaling, but integration challenges and operational complexities in managing a nationwide network need careful evaluation. The
For a company with a market cap of just
The strategic focus on interventional psychiatry practices, particularly those offering ketamine and TMS treatments, positions HOPE Therapeutics at the intersection of two growing trends: the mental health crisis and innovative treatment modalities. The targeting of established clinics with mature patient populations reduces initial patient acquisition costs and provides immediate revenue streams.
However, the fragmented nature of psychiatric practices and varying state regulations could present operational challenges in creating a standardized national network. The emphasis on multimodal care facilities indicates a comprehensive treatment approach, which could provide competitive advantages but also increases operational complexity.
The appointment of Dr. David Feifel as Chief Medical Innovation Officer, known for his work in neuropsychiatry, suggests a focus on maintaining clinical excellence while scaling. This workshop appears designed to secure funding for the next phase of an already-in-motion acquisition strategy, rather than testing initial market interest.
Jonathan Javitt, MD, MPH, Chairman, Co-CEO of HOPE Therapeutics and Chairman and Chief Scientist of NRx Pharmaceuticals, and David Feifel, MD, PhD, the designated Chief Medical Innovation Officer of HOPE Therapeutics, will provide a corporate update and entertain questions related to future HOPE clinic acquisitions.
The investor workshop will be conducted during the week of January 6, 2025 at a time to be disclosed to cleared participants. Qualified Institutional Investors, according to the definition of the US Securities and Exchange Commission, who may be prepared to commit a minimum of
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. () is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional 听psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at听. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
听
View original content to download multimedia:
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is HOPE Therapeutics' revenue target for clinic acquisitions in 2025 (NRXP)?
What is the minimum investment requirement for NRXP's HOPE Therapeutics investor workshop?
What types of treatment services will HOPE Therapeutics' acquired clinics offer (NRXP)?
When and where will HOPE Therapeutics' investor workshop take place (NRXP)?
